A dual-compartment metabolic engineering strategy simultaneously activated resveratrol biosynthesis in both the peroxisomes and cytoplasm of Saccharomyces cerevisiae. By targeting four enzymes — tyrosine ammonia-lyase, 4-coumarate-CoA ligase, stilbene synthase, and acetyl-CoA carboxylase — to peroxisomes via C-terminal signaling peptides, and amplifying three heterologous genes to 11 copies through multilocus integration, peroxisomal output improved 200%. Systematic engineering of malonyl-CoA, acetyl-CoA, and fatty acid nodes added a further 161% titer boost. Combined, the dual-compartment strain reached 552.16 mg/L resveratrol in 5-L bioreactors, with ¹³C flux analysis confirming additive contributions from each compartment.
Resveratrol's well-documented roles in sirtuin activation, AMPK signaling, and cardiovascular protection make scalable biosynthesis a legitimate longevity-adjacent research priority. Current plant-extraction yields are erratic and costly; prior yeast engineering efforts rarely exceeded 400 mg/L. The 552 mg/L benchmark here is meaningful, though industrial viability typically demands gram-per-liter scale. The peroxisome-as-factory concept is the genuinely novel contribution: compartmentalizing competing metabolic pathways reduces cytoplasmic flux interference, a principle transferable to other polyphenols like pterostilbene or piceatannol. Limitations are real — this is fermentation engineering, not a human trial, so direct health implications remain distant. However, lower production costs could make resveratrol more accessible for clinical dose-response research, where current studies are hampered by poor bioavailability and inconsistent sourcing. This is an incremental-to-notable advance in synthetic biology, with broader paradigmatic value for compartment-based biochemical manufacturing.